Advancing science. Improving connections.

We focus our research and development efforts on rare (affecting fewer than 200K patients in the U.S.) and near-rare (affecting fewer than one million patients) neuropsychiatric conditions.

Our lead product candidate, ZygelTM is a CBD gel currently being evaluated for Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD) in pediatric patients, 22q, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).

Clinical Pipeline and Expected Milestones

Clinical Pipeline

    

* Orphan Drug Designation

Ongoing
 
Planned

 

Upcoming Milestones

These timelines are subject to change due to regulatory, clinical and other considerations.